The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The University of Queensland has informed the Company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec® in India.
The granted patent in India is for a composition of matter patent for the particle itself as well as the manufacturing process relating to how the particle is made and matches the patents granted in the USA, Canada, Europe, Japan, Australia and China.
For a Company that has protected ‘Nuvec’ in all the major Global territories one has to consider the possibility of immense upside on a commercial agreement in the future.
The Company hasn’t gone to the effort & expense of protecting what it has designed, prior to announcing a Potential Partnership/agreement.
Perhaps the market is beginning to attribute some value to what The Company is planning, and protecting.
We now have Nanogenics as well as Nuvec at the cutting edge, both with huge potential.
* More than 75 million people worldwide are affected by Glaucoma = A big opportunity for N4P
* The total Glaucoma treatment market size in 2021 exceeded $5.5 billion and is growing = A big opportunity for N4P
* Other fibrotic treatments are also being targeted by Nanogenics , including for liver and lung fibrosis. = A big opportunity for N4P
In relation to Nuvec we know that:
* The number of approvals of new gene therapies and the need for appropriate delivery systems have reached unprecedented highs and demand is growing rapidly = A big opportunity for N4P
* The AAV vector market alone (AAV based gene therapy and AAV manufacturing) is projected to grow from USD 1.9 billion in 2022 to USD 11.1 billion by 2030 = A big opportunity for N4P
N4P is a slow burner but it it will only take one positive RNS re a licencing deal to change everything for N4P's MCAP and share price....
Good luck, Brighty
19 trades all last week and 37 today before 12 .
Yes leaky indeed 😉
We need to get some real meat on the bones.
Have a good feeling about the prospects but get tired of the same spill.
On the move on low volume. Does look a bit leaky. .9p paid. Imagine what this might do with some news of commerciality!
5 days on from my mess.volume now will take up
Good climb this morning. lets hope there's something driving it and not just another phantom rise
Hopefully finalising a deal!
Slightly better ,close above 0.80 poss back to 1.20 -1.30 (2000ema)
https://invst.ly/14c2x0
7 weeks since the last update ....
Come on Nigel ,what's happening ????
I need me money to back to go on holiday 🙏🙄 ...🤔
The risks are aplenty. Not just the need to commercialise before they run out of money but the many other competing research around the world. Their own research is very encouraging and two big investors recently have given a much needed vote of confidence. Unfortunately it is still very difficult to raise money in this sector. So those two seem pretty essential to helping this getting across the line.
Someone has faith and confidence. In my opinion it is a brave move. Perhaps they know something we don't! I've been watching this company for a long time and have a small amount invested in them. I do see it as a very high risk investment. But can't see the price dropping much lower than it is now. Potential for some serious upside if the right deals are done. Great product line in development.
Well someone bought £17k this morning.
I share your opinion Homer. in this day and age where we are bombarded with information constantly it amazes me that the company aren't marketing themselves.
i only need to be in the room with somebody who mentions they need a toaster and my social media pages will be flooded with toasters for weeks.
i google N4p every day and i have never seen a single marketing ad for them on any platform unless i search for them.
Share price at a near all-time low.
It doesn't bring out bad news. It's just that nobody ever hears of it.
I am beginning to hope we get bought out as it will stop me from looking at this terrible-run company.
Showing a 15% drop at one point today. Hopefully no more bad news on the way.
Maybe a Robin reliant at this rate…?
Cancel the Panda!
Would we be leaning towards positive or negative results if they take longer to release than previous years would you think?
The deadline is 30th June. They will be later than the last couple of years but not ' late late' unless after 30.06.24.
Final results for 2022 were given on the 23rd Feb.
Final results for 2023 were given on the 9th March.
Anyone know why they are late?
Indeed Johno. Maybe even trade up to a Panda!
Time to start revving the Punto.... Don't forget to use the choke...!
It was a press release of the article that has been doing the rounds of late:
https://www.ophthalmologytimes.com/view/n4-pharma-moving-novel-delivery-systems-towards-commercialization